Trial · NCT05293717
Topical Ruxolitinib in Chronic Hand Dermatitis
NCT05293717, Phase 1, Phase 2, Completed, University of Rochester; results first posted 2024-10-15
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Topical Ruxolitinib in Chronic Hand Dermatitis. Trials, record NCT05293717. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05293717
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Topical Ruxolitinib in Chronic Hand Dermatitis
- NCT number
- NCT05293717
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 16 participants, actual
- Lead sponsor
- University of Rochester
- Conditions
- Chronic Hand Dermatitis
- Interventions
- Ruxolitinib
- First posted
- 2022-03-24
- Last updated
- 2025-02-25
- Results first posted
- 2024-10-15
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment | week 12 | Proportion of patients achieving an Investigators Global Assessment (IGA) score of 0 or 1 with at least a 2-step improvement (IGA treatment success). The Investigator Global Assessment (IGA) will provide information of the overall disease. It is a 5-point scale: clear-1, almost clear-2, mild-3, moderate-4, and severe-5. |
| Primary | Percent Change in Mean Hand Eczema Severity Index (HECSI) | baseline to week 12 | Hand Eczema Severity Index (HECSI) , a well-accepted and validated scoring system for disease activity. It incorporates both the extent and the intensity of the disease. Each hand is divided into five areas: fingertips, fingers (except the tips), palms, back of hands and wrists. Each area will be scored for extension and intensity of the six following clinical signs: erythema, induration /papulation, vesicles, fissuring, scaling, and edema; which are graded on the following scale: 0, no skin changes; 1, mild disease; 2, moderate and 3, severe. Data will be reported as a percent change in the HECSI score from baseline to week 12. The score ranges from 0-360. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment | week 12 | proportion of participants | NUMBER | |
| PRIMARY | Percent Change in Mean Hand Eczema Severity Index (HECSI) | baseline to week 12 | percent change of HECSI index | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment | All Participants | 0.53 | proportion of participants | ||
| Percent Change in Mean Hand Eczema Severity Index (HECSI) | All Participants | -86.2 | Standard Error 3.72 | percent change of HECSI index |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | All Participants | 16 | |
| Overall Study | COMPLETED | All Participants | 15 | |
| Overall Study | NOT COMPLETED | All Participants | 1 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper Respiratory Infection | Infections and infestations | All Participants | 1 | 16 | |
| other | scalp abscess | Infections and infestations | All Participants | 1 | 16 | |
| serious | kidney stone | Renal and urinary disorders | All Participants | 1 | 16 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | All Participants | 0 | 16 |
| Total, other adverse events | All Participants | 2 | 16 |
| Total, serious adverse events | All Participants | 1 | 16 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05293717
GET https://conductscience.org/api/trials/v1/NCT05293717/registered